The rebate game played by drug makers and pharmacy benefit managers limits optimal biosimilar competition. As a result, U.S.

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move could jeopardize the availability of cheaper, generic forms of those drugs ...

Treatment availability and patient outcomes are critical issues for the pharmaceutical industry, particularly in eye care.

Some patients are facing delays or breaks in their treatment due to shortages of certain medicines, with hundreds of drugs ...

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

Cetuximab was on a list of 13 medications the National Party promised to fund ... step forward”, but his organisation hoped ...

The federal competition watchdog said more information is needed on the impacts of exclusive deals between drug insurers and ...

Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of ...

The AI model transcribes calls from the public to emergency responders and automatically fills out a form that call-takers ..

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

For many patients on tirzepatide ... to supply the market with commercial medications. If a drug's total supply can't meet current demand, the FDA will list it as in shortage.